



RECEIVED
U.S. SENATE
01 FEB -9 PM 3:33
GENZYME CORPORATION
1020 NINETEENTH STREET, N.W.
SUITE 550
WASHINGTON, D.C. 20036
202-296-3280
FAX 202-296-3411

9 February, 2001

The Honorable Gary Sisco
Secretary of the Senate
Office of Public Records
232 Hart Senate Office Building
Washington, D.C. 20510

Dear Mr. Sisco:

Enclosed please find an original copy of our Lobbying Report (#16054-12) for midyear, July 1 through December 31, 2000.

If you should have any questions, please do not hesitate to contact me.

Sincerely,

Lisa J. Raines
Senior Vice President
Government Relations

Enc. (1)

Clerk of the House of Representatives
 Legislative Resource Center
 B-106 Cannon Building
 Washington, DC 20515

Secretary of the Senate
 Office of Public Records
 232 Hart Building
 Washington, DC 20510

RECEIVED
 SECRETARY OF THE SENATE

01 FEB -9 PM 3:33

LOBBYING REPORT


Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name <u>Genzyme Corporation</u>			
2. Address <input type="checkbox"/> Check if different than previously reported <u>1020 Nineteenth Street, NW, Suite 550, Washington, DC 20036</u>			
3. Principal Place of Business (if different from line 2) City: <u>Cambridge</u> State/Zip (or Country) <u>MA 02139</u>			
4. Contact Name <u>Lisa Raines</u>	Telephone <u>(202) 296-3280</u>	E-mail (optional)	5. Senate ID # <u>16054-12</u>
7. Client Name <input checked="" type="checkbox"/> Self	6. House ID # <u>30257000</u>		

TYPE OF REPORT 8. Year 2000 Midyear (January 1-June 30) OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report
 10. Check if this is a Termination Report → Termination Date _____ 11. No Lobbying Activity

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13	
<p>12. Lobbying Firms</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇒ \$ _____ <small>Income (nearest \$20,000)</small></p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p>13. Organizations</p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> ⇒ \$ <u>540,000</u> <small>Expenses (nearest \$20,000)</small></p> <p>14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options.</p> <p><input type="checkbox"/> Method A: Reporting amounts using LDA definitions only</p> <p><input type="checkbox"/> Method B: Reporting amounts under section 6033(b)(8) of the Internal Revenue Code</p> <p><input checked="" type="checkbox"/> Method C: Reporting amounts under section 162(e) of the Internal Revenue Code</p>

Signature 
 Printed Name and Title Lisa Raines, Senior Vice President, Government Relations

Registrant Name Genzyme Corporation (16054-12)

Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.**

15. General issue area code MED (one per page)

16. Specific lobbying issues

a. Federal oversight and regulation of gene therapy research

b. Privacy issues:

S. 573 - "Medical Information Privacy and Security Act"

S. 881 - "Medical Information Protection Act of 1999"

H.R. 1057 - "Medical Information Privacy and Security Act"

H.R. 1941 - "Health Information Privacy Act"

H.R. 2470 - "Medical Information Protection and Research Enhancement Act of 1999"

17. House(s) of Congress and Federal agencies contacted

Check if None

a. United States Senate

United States House of Representatives

Executive Office of the President

Department of Health and Human Services

b. United States Senate

United States House of Representatives


18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Lisa J. Raines		<input type="checkbox"/>
Mary McGrane		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each such foreign entity in the specific issues listed on line 16 above

Check if None

Signature



Date: 9 February 2001

Printed Name and Title

Lisa Raines, Senior Vice President, Government Relations

Registrant Name Genzyme Corporation (16054-12)

Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TAX (one per page)

16. Specific lobbying issues

Oppose Administration's proposed tax on the issuance of tracking stock
Support expansion of orphan drug tax credit (H.R. 2990, "Quality Care for the Uninsured Act of 1999,"
Section 206)


17. House(s) of Congress and Federal agencies contacted Check if None

United States Senate
United States House of Representatives
Executive Office of the President
Department of Health and Human Services

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Lisa J. Raines		<input type="checkbox"/>
Mary McGrane		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each such foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date: 9 February 2001
Printed Name and Title Lisa Raines, Senior Vice President, Government Relations

Registrant Name Genzyme Corporation (16054-17)

Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

a) Support Medicare coverage of oral phosphate-binding drugs

b) Medicare Prescription Drug Benefit:

- S. 731/H.R. 664 - "Prescription Drug Fairness for Seniors Act of 1999"
- S. 841/H.R. 1495 - "Access to Rx Medications in Medicare Act of 1999"
- S. 1480/H.R. 2787 - "Seniors Prescription Insurance Coverage Equity (SPICE) Act of 1999"
- H.R. 4680 - "Medicare Rx Drug 2000 Act"
- H.R. 4607 - "Medicare Prescription Drug Act of 2000"
- H.R. 4770 - "Medicare Guaranteed and Defined Rx Benefit and Health Provider Relief Act of 2000"
- S. 2342 - "Medicare Modernization Act of 2000"
- S. 2807 - "Medicare Prescription Drug and Modernization Act of 2000"
- S. 2758 - "Medicare Outpatient Drug Act of 2000"
- S. 1895 - "Medicare Preservation and Improvement Act of 1999"
- S. 2753 - "Medicare Expansion for Needed Drugs (MEND) Act of 2000"
- S. 2836 - "Medicare Rx Drug Discount and Security Act of 2000"
- S. 1725 - "DrugGap Insurance for Seniors Act of 1999"
- H.R. 5543 - "Medicare, Medicaid, and SCHIP Benefits Improvement and Protection Act of 2000"
(Section 429 "Revised Part B payment for drugs and biologicals and related services")
- S. 3165 - "The Medicare, Medicaid, and SCHIP Improvement Act of 2000"
(Section 104 "Moratorium on reductions in correct reimbursement rates for outpatient drugs and biologicals; GAO study and report and HHS comments)
- H.R. 5661 - "Medicare, Medicaid and SCHIP Benefits Improvement Act of 2000"
(Section 429 "Revised Part B payment for drugs and biologicals and related services")
- H.R. 4577/P.L. 106-554 - "The Consolidated Appropriations Act for 2001" (incorporates text of H.R. 5661)
- H.R. 2925 - "Medicare Beneficiary Prescription Drug Assistance and Stop-Loss Protection Act of 1999"

17. House(s) of Congress and Federal agencies contacted Check if None

United States Senate
United States House of Representatives
Executive Office of the President
Department of Health and Human Services

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Lisa J. Raines		<input type="checkbox"/>
Mary McGrane		<input type="checkbox"/>

19. Interest of each such foreign entity in the specific issues listed on line 16 above Check if None

Signature 

Date: 9 February 2001

Printed Name and Title Lisa Raines, Senior Vice President, Government Relations

Registrant Name Genzyme Corporation (16054-12)

Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code INS (one per page)

16. Specific lobbying issues

- a) Support provisions prohibiting health plans from labeling FDA approved products as "experimental" or "investigational":
 - S. 6 - "Patients' Bill of Rights Act of 1999"
 - S. 240 - "Patients' Bill of Rights Act of 1999"
 - S. 300 - "Patients' Bill of Rights Plus Act"
 - S. 326 - "Patients' Bill of Rights Act"
 - S. 1256 - "Patients' Bill of Rights Act of 1999"
 - S. 1344 - "Patients' Bill of Rights Plus Act"
 - S. 3057 - "Patients' Bill of Rights Act"
 - S. 3058 - "Patients' Bill of Rights Act"
 - H.R. 306 - "Genetic Information Nondiscrimination in Health Insurance Act of 1999"
 - H.R. 358 - "Patients' Bill of Rights Act of 1999"
 - H.R. 2457 - "Genetic Nondiscrimination in Health Insurance and Employment Act of 1999"
 - H.R. 2723 - "Bipartisan Consensus Managed Care Improvement Act of 1999"
 - H.R. 2990 - "Quality Care for the Uninsured Act of 1999"
- b) Genetic discrimination issues
 - H.R. 2457 - "Genetic Non-discrimination in Health Insurance and Employment Act of 1999"
 - H.R. 306 - "Genetic Information Nondiscrimination in Health Insurance Act of 1999"


17. House(s) of Congress and Federal agencies contacted Check if None

United States Senate
 United States House of Representatives
 Executive Office of the President
 Department of Health and Human Services

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Lisa J. Raines		<input type="checkbox"/>
Mary McGrane		<input type="checkbox"/>

19. Interest of each such foreign entity in the specific issues listed on line 16 above Check if None

Signature 

Date: 9 February 2001

Printed Name and Title Lisa Raines, Senior Vice President, Government Relations

Registrant Name Genzyme Corporation (16054-12)

Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific lobbying issues

- S. 2536 – Agriculture FY2000 Appropriations bill, Chapter 8, Section 2801 (provision relating to extension of Cotransformation Patent)
- H.R. 4461 – FY 2001 Agriculture Appropriations bill, Chapter 8, Section 2801 (potential provision relating to extension of Cotransformation Patent)
- H.R. 4425/S. 2551 – Military Construction FY2001 Appropriations bill (potential provision relating to extension of Cotransformation Patent)
- H.R. 4576/S. 2593 – FY2001 Defense Appropriations bill (potential provision relating to extension of Cotransformation Patent)


17. House(s) of Congress and Federal agencies contacted Check if None

United States Senate
United States House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Lisa J. Raines		<input type="checkbox"/>
Mary McGrane		<input type="checkbox"/>

19. Interest of each such foreign entity in the specific issues listed on line 16 above Check if None

Signature 

Date: 9 February 2001

Printed Name and Title Lisa Raines, Senior Vice President, Government Relations

Registrant Name Genzyme Corporation (16054-12)

Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code PHA (one per page)

16. Specific lobbying issues

H.R. 3677	"Thomas Navarro FDA Patient Rights Act"
H.R. 4461	FY2001 Agricultural Appropriations bill (report language re: orphan biologicals)
H.R. 4242	"Orphan Drug Innovation Act"


17. House(s) of Congress and Federal agencies contacted Check if None

United States House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Lisa J. Raines		<input type="checkbox"/>
Mary McGrane		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each such foreign entity in the specific issues listed on line 16 above Check if None

Signature 

Date: 9 February 2001

Printed Name and Title Lisa Raines, Senior Vice President, Government Relations

Registrant Name Genzyme Corporation (16054-12)

Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

S. 1981 - "Genetics and Public Health Services Act"

17. House(s) of Congress and Federal agencies contacted

Check if None


United States Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Lisa J. Raines		<input type="checkbox"/>
Mary McGrane		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each such foreign entity in the specific issues listed on line 16 above

Check if None

Signature 

Date: 9 February 2001

Printed Name and Title Lisa Raines, Senior Vice President, Government Relations